On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the ...

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly ...

Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of ...

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...

ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Cancer continues to be a formidable challenge globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies altering the landscape of cancer prognosis and ...

Intellia Therapeutics reported better-than-expected third-quarter earnings, highlighting advancements in its CRISPR ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on NTLA stock, giving a Buy rating today. Whitney Ijem has given ...

Editas Medicine EDIT incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported a loss of 55 cents ...

Introduction to HEK 293 Cells HEK 293 cells, also known as Human Embryonic Kidney 293 cells, have become a crucial tool in ...